1
|
Garbayo-Salmons P, Vilarrasa E, Bassas-Vila J, Mora-Fernández V, Fuertes I, Luque-Luna M, Fornons-Servent R, Martin-Ezquerra G, Aguayo-Ortiz RS, Ceravalls J, Mollet J, Gómez Tomás Á, Masferrer E, Corral-Magaña O, Matas-Nadal C, Del Estal J, Fuertes Bailón D, Calvet J, Romaní J. Real-world adalimumab survival and discontinuation factors in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2024. [PMID: 38687278 DOI: 10.1111/jdv.20044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2024] [Accepted: 03/11/2024] [Indexed: 05/02/2024]
Abstract
BACKGROUND AND OBJECTIVES Survival analyses can provide valuable insights into effectiveness and safety as perceived by prescribers. Here, we aimed to evaluate adalimumab (ADA) survival and the interruption risk factors in a multicentre cohort of patients with hidradenitis suppurativa (HS). Moreover, we performed a subanalysis considering the periods before and after the onset of the COVID-19 pandemic. METHODS We conducted a retrospective study including 539 adult patients with HS who received ADA from 1 May 2015 to 31 December 2022. Overall drug survival was analysed using Kaplan-Meier survival curves and compared between the subgroups via stratified log-rank test. Possible predictors for overall drug survival and reasons for discontinuation were assessed using univariate and multivariate Cox regression. RESULTS Overall, 50.1% were females with a mean age of 43.5 ± 1 years and a mean BMI of 29.5 ± 6.7. At the start of ADA, 95.29% were biologic-naïve and 24.63% had undergone surgical treatment. During follow-up, 9.46% of patients required dose escalation, while 39.92% interrupted ADA. Concomitant therapy was used in 64.89% of cases. A subanalyses comparing pre- and post-pandemic periods revealed a tendency to initiate ADA treatment at a younger age, among patient with higher BMI and at a lower HS stage after COVID-19 pandemic. Interestingly, ADA demonstrated extended survival compared to previous studies, with a median overall drug survival of 56.2 months (95% CI 51.2 to 80.3). The primary causes for discontinuation were inefficacy (51.69%), followed by adverse effects (21.35%). Female sex, longer delay in HS diagnosis, higher baseline IHS4 score and concomitant spondyloarthritis were associated with poorer ADA survival or increased risk of discontinuation. CONCLUSIONS ADA demonstrated prolonged survival (median 56.2 months). While addition of antibiotics did not have a positive effect on survival rate, basal IHS4 proved useful in predicting ADA survival.
Collapse
Affiliation(s)
- Patricia Garbayo-Salmons
- Dermatology Department, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Sabadell, Spain
- Departament de Medicina, Universitat Autònoma de Barcelona, Sabadell, Spain
| | - Eva Vilarrasa
- Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Julio Bassas-Vila
- Dermatology Department, Hospital Germans Trias i Pujol, Barcelona, Spain
| | | | - Irene Fuertes
- Dermatology Department, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Mar Luque-Luna
- Dermatology Department, Hospital Clínic de Barcelona, Barcelona, Spain
| | | | | | | | - Joan Ceravalls
- Dermatology Department, Hospital Universitari Sagrat Cor, Grupo Quirónsalud, Barcelona, Spain
| | - Jordi Mollet
- Dermatology Department, Hospital Vall d'Hebrón, Barcelona, Spain
| | | | - Emili Masferrer
- Dermatology Department, Hospital Universitari Mútua Terrassa, Terrassa, Spain
| | - Oriol Corral-Magaña
- Dermatology Department, Hospital Universitari Mútua Terrassa, Terrassa, Spain
| | - Clara Matas-Nadal
- Dermatology Department, Hospital de Santa Caterina de Girona, Girona, Spain
| | - Jorge Del Estal
- Pharmacy Department, Parc Taulí Hospital Universitari, Universitat Autònoma de Barcelona, Sabadell, Spain
| | - Diana Fuertes Bailón
- Research Support Unit, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, Sabadell, Spain
| | - Joan Calvet
- Departament de Medicina, Universitat Autònoma de Barcelona, Sabadell, Spain
- Rheumatology Department, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Sabadell, Spain
| | - Jorge Romaní
- Dermatology Department, Hospital General de Granollers, Granollers, Spain
| |
Collapse
|
3
|
Mora-Fernández V, Mercader Garcia P, Borrego Hernando L, González Pérez R, Córdoba Guijarro S, Giménez Arnau A, Ruiz González I, Miquel Miquel F, Silvestre Salvador J, Ortiz de Frutos F, Sanz Sanchez T, Rodríguez Serna M, Fernández Redondo V, Sanchez Perez J, Heras Mendaza F, Serra Baldrich E, Zaragoza Ninet V, Pastor Nieto M, Hervella Garcia M, Garcia Doval I, Carrascosa J. Perfil epidemiológico, clínico, y alérgico en pacientes con dermatitis atópica y dermatitis de las manos. Evaluación del Registro Español de Dermatitis de Contacto (REIDAC). Actas Dermo-Sifiliográficas 2022; 113:236-243. [DOI: 10.1016/j.ad.2021.10.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2021] [Revised: 09/27/2021] [Accepted: 10/04/2021] [Indexed: 11/30/2022] Open
|
4
|
Mora-Fernández V, Mercader Garcia P, Borrego Hernando L, González Pérez R, Córdoba Guijarro S, Giménez Arnau A, Ruiz González I, Miquel Miquel F, Silvestre Salvador J, Ortiz de Frutos F, Sanz Sanchez T, Rodríguez Serna M, Fernández Redondo V, Sanchez Perez J, Heras Mendaza F, Serra Baldrich E, Zaragoza Ninet V, Pastor Nieto M, Hervella Garcia M, Garcia Doval I, Carrascosa J. [Translated article] Epidemiological, Clinical, and Allergy Profile of Patients With Atopic Dermatitis and Hand Eczema: Evaluation of the Spanish Contact Dermatitis Registry (REIDAC). Actas Dermo-Sifiliográficas 2022. [DOI: 10.1016/j.ad.2022.02.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
|